ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 626-650 of 1,000 matching filings.

Per page
25
Current page
26
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
21 Jul 2021
Reporting date
21 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ACQUISITION OF ALEXION COMPLETED

Filing date
21 Jul 2021
Reporting date
21 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
F-6EF File 333-258002

REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES

Filing date
19 Jul 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC

Filing date
19 Jul 2021
Reporting date
19 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT

Filing date
16 Jul 2021
Reporting date
16 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
14 Jul 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
14 Jul 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK

Filing date
14 Jul 2021
Reporting date
14 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA

Filing date
08 Jul 2021
Reporting date
08 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
06 Jul 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
06 Jul 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU

Filing date
06 Jul 2021
Reporting date
06 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2021
Reporting date
01 Jul 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
30 Jun 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

FORM 11-K

Filing date
29 Jun 2021
Reporting date
31 Dec 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD

Filing date
28 Jun 2021
Reporting date
28 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE

Filing date
28 Jun 2021
Reporting date
28 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER

Filing date
24 Jun 2021
Reporting date
24 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ORPATHYS APPROVED IN CHINA FOR LUNG CANCER

Filing date
23 Jun 2021
Reporting date
23 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1

Filing date
22 Jun 2021
Reporting date
22 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON AZD7442 STORM CHASER TRIAL

Filing date
15 Jun 2021
Reporting date
15 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB

Filing date
07 Jun 2021
Reporting date
07 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
04 Jun 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
425

425

Filing date
04 Jun 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER

Filing date
04 Jun 2021
Reporting date
04 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .